Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of RGL-2102 for severe lower limb ischemia
CTR20250159Phase 2Active
- Sponsor
- Neurophth
- Start
- Jan 2025
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lower extremity ischemia (PAD) and chronic limb-threatening ischemia (CLTI) comparing RGL-2102 with Placebo (2 arms). Started Jan 2025; status: active.
02
Drugs
RGL-2102
03
Conditions
lower extremity ischemia (PAD)chronic limb-threatening ischemia (CLTI)
Beyond the preview
Go deeper on CTR20250159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250159.